SMITH-&-NEPHEW
Smith & Nephew (LSE:SN) (NYSE:SNN), the global medical technology business, announces the conclusion of the 6th International Negative Pressure Wound Therapy (NPWT) Expert Meeting. 300 international experts convened in Berlin between 20-21st March. 35 speakers from 11 countries defined the challenges of surgical site complications, sharing new evidence on clinical outcomes of using Smith & Nephew’s PICO◊ , a unique, canister-free NPWT system for reducing closed incision complications in high risk patients. Evidence for PICO on closed incisions is growing in a number of surgical areas, including orthopaedic, cardiothoracic and plastic surgery.1-4 The Meeting saw data from 14 studies involving PICO, including 7 randomised controlled trials across different niches.
Complications can be devastating for the patient and it’s estimated they can double the cost of the initial surgery5 . NPWT helps prevent wound complications by stimulating blood flow in the peri-incisional area, removing excess fluid, helping reduce oedema, and stabilising the incision site by reducing lateral tension. These actions work together to reduce complications such as surgical dehiscence, seroma and haematoma formation and surgical site infections (SSIs).6-9
A recent, international, multi-centre RCT3 involving 200 bilateral breast reduction patients found PICO significantly reduced incidence of surgical dehiscence, and improved the visual appearance of the scar at 42 and 90 days post-surgery. Professor Donald Hudson, Head of Department, Plastic and Reconstructive Surgery, University of Cape Town and Groote Schuur Hospital, South Africa: “There’s no doubt that indications will extend to all aspects of breast surgery such as onco-plastic and reconstructive surgery. There are early suggestions that scarring is better with PICO, so I see this product extending into cosmetic surgery.”
Mr John Murphy, Consultant Onco-plastic, Reconstruction and Cosmetic Breast Surgeon at University Hospital South Manchester, presented clinical experience of using PICO in complex breast reconstructions after mastectomy. He underlined the need for interventions to help oncology patients avoid psychological effects of complications and the potential impact of therapies such as chemotherapy or radiotherapy.
Mr Michael Sugrue, Consultant Breast and General Surgeon, Letterkenny General Hospital/UCHG, County Donegal: “The impact of NPWT is enormous. We’ve opened our minds to the future: negative pressure has a place in it.”
◊ Trademark of Smith & Nephew. Registered US Patent and Trademark Office.
Full press release, video and references: http://www.smith-nephew.com/news-and-media/media-releases/news/6th-npwt-expert-meeting-pico-evidence/
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20150401005034/en/
Contact:
Smith & Nephew
Rachel Cunningham
+44-20-8995-5832
rachel@ROADCommunications.co.uk
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
KIOXIA and Linus Media Group Set World Record for Pi Calculation19.5.2025 08:00:00 CEST | Press release
New GUINNESS WORLD RECORDS Title for Most Accurate Value of Pi - 300 Trillion Digits Calculated Using KIOXIA NVMe™ SSDs Kioxia Corporation, a world leader in memory solutions, today announced that it has collaborated with Linus Media Group, creator of Linus Tech Tips and other influential technology-focused YouTubeTM channels, to set a new GUINNESS WORLD RECORDS® title for the Most Accurate Value of Pi. A groundbreaking 300 trillion digits were calculated and have been officially verified and confirmed by Guinness World Records1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250518801709/en/ KIOXIA SSD The record-smashing computation was enabled by a high-performance storage cluster comprising 2.2 petabytes (PB)2 of 30.72 terabyte (TB) CM Series and 15.36 TB CD Series PCIe® NVMe™-based solid-state drives (SSDs) from KIOXIA. These SSDs were configured in a network-attached storage environment connected to a dual-CPU compute
NetApp Builds AI Infrastructure on NVIDIA AI Data Platform19.5.2025 08:00:00 CEST | Press release
Businesses using NetApp AIPod can accelerate AI agents and speed up retrieval of relevant information NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that it is working with NVIDIA to support the NVIDIA AI Data Platform reference design in the NetApp AIPod solution to accelerate enterprise adoption of agentic AI. Powered by the robust and mature data management capabilities of NetApp ONTAP®, NetApp AIPod deployments built on the NVIDIA AI Data Platform will help businesses build secure, governed, and scalable AI data pipelines for retrieval-augmented generation (RAG) and inferencing, enabling organizations to harness the full potential of AI innovation. As businesses invest in AI to solve complex business challenges, they need intelligent data infrastructure that can remove the data silos that slow technical innovation. The most recent NetApp Data Complexity report found that 79 percent of tech and business leaders agree that unifying their data est
Fujirebio Receives Marketing Clearance for Lumipulse®G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease17.5.2025 08:58:00 CEST | Press release
—First Blood-Based In-Vitro Diagnostic Test to Receive FDA Clearancefor Patients Being Assessed for Alzheimer’s Disease. ——Availability of Accurate, Accessible, Blood-Based Diagnostic Tests Will Aid in Development and Availability of More Effective Interventions for Alzheimer’s Disease — Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test for the assessment of amyloid pathology in patients being evaluated for Alzheimer’s disease and other causes of cognitive decline. The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA cleared blood-based IVD test in the U.S. to aid to identify patients with amyloid pathology associated with Alzheimer’s Disease (AD). Alzheimer’s disease currently affects an estimated 7.2 million Americans, a number projected to rise to nearly 14 million by 2060.1 It is a leading cause
IFF Announces Pricing of Tender Offers For Certain Outstanding Series of Notes16.5.2025 23:17:00 CEST | Press release
IFF (NYSE: IFF) announced today the Total Consideration (as defined below) payable in connection with its previously announced tender offers to purchase for cash: (i) up to $1,100,000,000 aggregate purchase price, excluding accrued and unpaid interest (the “Amended Pool 1 Maximum Amount”), of its 1.230% Senior Notes due 2025 (the “2025 Notes”), 1.832% Senior Notes due 2027 (the “2027 Notes”), 4.450% Senior Notes due 2028 (the “2028 Notes”) and 2.300% Senior Notes due 2030 (the “2030 Notes” and collectively with the 2025 Notes, the 2027 Notes and the 2028 Notes, the “Pool 1 Notes”) and (ii) up to $900,000,000 aggregate purchase price, excluding accrued and unpaid interest (the “Amended Pool 2 Maximum Amount” and, together with the Amended Pool 1 Maximum Amount, the “Amended Maximum Amounts”), of its 3.268% Senior Notes due 2040 (the “2040 Notes”), 4.375% Senior Notes due 2047 (the “2047 Notes”), 5.000% Senior Notes due 2048 (the “2048 Notes”) and 3.468% Senior Notes due 2050 (the “2050
Origins Launches in the U.S. Amazon Premium Beauty Store16.5.2025 15:00:00 CEST | Press release
The brand brings its high-performance, clinically proven, nature-inspired skincare to Amazon shoppers Origins, with over 30 years of expertise in combining naturally-derived and scientifically crafted ingredients for powerful skincare, announced its official debut in the U.S. Amazon Premium Beauty store today. Origins will offer its iconic skincare and body care products along with giftable sets that are perfect for any occasion. Origins will now bring naturally-derived, effective beauty to Amazon customers nationwide with convenience and thoughtful gifting in mind. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250516435958/en/ This launch marks a strategic step in Origins’ ongoing efforts to meet the evolving needs of skincare shoppers, seeking high-performance, conscious beauty on their favorite platforms. By expanding to the U.S. Amazon Premium Beauty store, Origins reinforces its commitment to delivering both efficacy a
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum